Ventiv Scientific today announced the successful completion of first-in-human clinical cases using the V-PULSE Mechanical Thrombectomy System, a novel platform designed to remove blood clots from peripheral vasculature. The system aims to address limitations of conventional aspiration thrombectomy by providing physicians with real-time control over aspiration force at the catheter tip.
Mechanical thrombectomy is a critical treatment for patients with thrombotic and embolic vascular disease, restoring blood flow, relieving symptoms, preserving limbs, and saving lives. It is commonly used for deep vein thrombosis, acute limb ischemia, critical limb ischemia, chronic total occlusions, pulmonary embolism, and other peripheral vascular conditions.
Makmood Razavi, M.D., of St. Joseph Heart & Vascular Center in Orange, CA, stated, "The V-PULSE system removed significant clot burden and provided immediate visual confirmation of thrombus capture through its integrated filtration technology. In our initial experience, the device demonstrated excellent control and procedural efficiency."
Unlike conventional systems that rely on continuous vacuum from syringes or electromechanical pumps, V-PULSE enables clinicians to rapidly start, stop, increase, or decrease aspiration, potentially minimizing catheter clogging and reducing procedural blood loss. John O'Connor, President of Ventiv Scientific, explained, "Aspiration thrombectomy systems can remove substantial volumes of blood while attempting to extract thrombus. The V-PULSE platform was engineered to provide physicians with procedural control, optimize aspiration efficiency, and potentially reduce blood loss while remaining compatible with existing aspiration pumps."
During thrombectomy, physicians advance a catheter to the clot site and apply aspiration to remove obstructive thrombus. Success depends on clot age, composition, location, catheter design, and aspiration force. V-PULSE was developed to address these challenges through a differentiated aspiration-control platform.
Ventiv Scientific's current thrombectomy portfolio includes the FDA-cleared Control Aspire Mechanical Thrombectomy System, with over-the-wire catheters for peripheral use and rapid-exchange catheter systems for peripheral and coronary applications. The company is also developing next-generation technologies, including a multi-strut thrombectomy basket retrieval platform. These investigational products have not been cleared by the FDA.
Ventiv Scientific is a privately held medical device company focused on innovative technologies for vascular intervention. For more information, visit www.ventivscientific.com.
